Thapa B, Caimi PF, Ardeshna KM, et al. CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv. 2020;4(16):3850-3852.

類似資料

• CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy
  著者:: Thapa, Bicky, 等
  出版事項: (2020)
• CD19/CD22 Dual‐Targeted CAR‐T Therapy Active in Relapsed/Refractory DLBCL
  出版事項: (2020)
• Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL
  著者:: Tabbara, Nadeem, 等
  出版事項: (2021)
• CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
  著者:: Liang, Yun, 等
  出版事項: (2021)
• CD5 and CD43 Expression are Associate with Poor Prognosis in DLBCL Patients
  著者:: Huang, Hui, 等
  出版事項: (2018)